Table 1 Efficacy of concurrent immunoradiotherapy
From: Immunotherapy Bridge 2018 and Melanoma Bridge 2018: meeting abstracts
| Â | All | Nivo-RT | Ipi-RT | ||||||
|---|---|---|---|---|---|---|---|---|---|
All | Inside | Outside | All | Inside | Outside | All | Inside | Outside | |
CR | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 |
PR | 5 | 10 | 0 | 5 | 8 | 0 | 0 | 2 | 0 |
SD | 2 | 4 | 7 | 1 | 0 | 6 | 1 | 4 | 1 |
PD | 12 | 1 | 12 | 4 | 0 | 4 | 8 | 1 | 8 |
NE | 0 | 4 | 0 | 0 | 2 | 0 | 0 | 2 | 0 |
Response rate (%) | 30.0 | 68.8 | 5.0 | 50.0 | 100.0 | 0.0 | 10.0 | 37.5 | 10.0 |
Disease control rate (%) | 40.0 | 93.8 | 40.0 | 60.0 | 100.0 | 60.0 | 20.0 | 87.5 | 20.0 |